CN114828891A - 以异常干细胞为靶标的糖尿病治疗 - Google Patents

以异常干细胞为靶标的糖尿病治疗 Download PDF

Info

Publication number
CN114828891A
CN114828891A CN202080087365.6A CN202080087365A CN114828891A CN 114828891 A CN114828891 A CN 114828891A CN 202080087365 A CN202080087365 A CN 202080087365A CN 114828891 A CN114828891 A CN 114828891A
Authority
CN
China
Prior art keywords
diabetes
abnormal
cells
stem cells
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080087365.6A
Other languages
English (en)
Chinese (zh)
Inventor
小岛秀人
寺岛智也
樫美和子
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biotz Procode
Original Assignee
Biotz Procode
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotz Procode filed Critical Biotz Procode
Publication of CN114828891A publication Critical patent/CN114828891A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2836—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD106
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202080087365.6A 2019-10-18 2020-10-16 以异常干细胞为靶标的糖尿病治疗 Pending CN114828891A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019191363 2019-10-18
JP2019-191363 2019-10-18
PCT/JP2020/039044 WO2021075535A1 (ja) 2019-10-18 2020-10-16 異常幹細胞を標的とする糖尿病治療

Publications (1)

Publication Number Publication Date
CN114828891A true CN114828891A (zh) 2022-07-29

Family

ID=75538122

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080087365.6A Pending CN114828891A (zh) 2019-10-18 2020-10-16 以异常干细胞为靶标的糖尿病治疗

Country Status (7)

Country Link
US (1) US20230025003A1 (https=)
EP (1) EP4035679A4 (https=)
JP (2) JPWO2021075535A1 (https=)
KR (1) KR20220103111A (https=)
CN (1) CN114828891A (https=)
AU (1) AU2020368759A1 (https=)
WO (1) WO2021075535A1 (https=)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090093398A1 (en) * 2003-11-07 2009-04-09 Jacques Bollekens Use of Fibroblast Growth Factor Fragments
CN101674820A (zh) * 2006-12-26 2010-03-17 药品循环公司 在联合治疗中应用组蛋白脱乙酰酶抑制剂并监测生物标记的方法
WO2010053316A2 (en) * 2008-11-06 2010-05-14 Snu R&Db Foundation New use of sixth immunoglobulin-like domain of vcam-1
CN101745112A (zh) * 2002-07-19 2010-06-23 艾博特生物技术有限公司 TNFα相关疾病的治疗
CN105640944A (zh) * 2014-12-02 2016-06-08 杨美宁 一种降低2型糖尿病合并冠心病患者sVCAM-1的方法
CN109072303A (zh) * 2016-02-05 2018-12-21 詹森生物科技公司 用于治疗或预防1型糖尿病的抗tnf抗体、组合物、方法和用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0671936A1 (en) * 1992-10-15 1995-09-20 Dana-Farber Cancer Institute, Inc. TREATMENT OF INSULIN RESISTANCE IN OBESITY LINKED TYPE II DIABETES USING ANTAGONISTS TO TNF-$g(a) FUNCTION
WO2011049412A2 (en) * 2009-10-23 2011-04-28 Hanwha Chemical Corporation Human recombinant monoclonal antibody that specifically binds to vcam-1 and inhibits adhesion and transmigration between leukocytes and endothelial cells
JP2019191363A (ja) 2018-04-25 2019-10-31 京セラドキュメントソリューションズ株式会社 定着装置及び画像形成装置

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101745112A (zh) * 2002-07-19 2010-06-23 艾博特生物技术有限公司 TNFα相关疾病的治疗
US20090093398A1 (en) * 2003-11-07 2009-04-09 Jacques Bollekens Use of Fibroblast Growth Factor Fragments
CN101674820A (zh) * 2006-12-26 2010-03-17 药品循环公司 在联合治疗中应用组蛋白脱乙酰酶抑制剂并监测生物标记的方法
WO2010053316A2 (en) * 2008-11-06 2010-05-14 Snu R&Db Foundation New use of sixth immunoglobulin-like domain of vcam-1
CN105640944A (zh) * 2014-12-02 2016-06-08 杨美宁 一种降低2型糖尿病合并冠心病患者sVCAM-1的方法
CN109072303A (zh) * 2016-02-05 2018-12-21 詹森生物科技公司 用于治疗或预防1型糖尿病的抗tnf抗体、组合物、方法和用途

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
国家食品药品监督管理局药品审评中心编: "《药品技术评价文集 第3辑》", 31 March 2009, 中国医药科技出版社, pages: 28 *
沈柏均主编: "《人类脐血 基础与临床》", 30 November 2016, 山东大学出版社, pages: 385 *
王华新主编: "《激素免疫分析与临床》", 31 May 2012, 人民军医出版社, pages: 178 - 179 *
秦川主编: "《实验动物学》", 31 January 2016, 中国协和医科大学出版社, pages: 81 - 83 *
苏式兵主编: "《生命科学前沿技术与中医药研究》", 30 September 2013, 上海浦江教育出版社, pages: 166 *

Also Published As

Publication number Publication date
JPWO2021075535A1 (https=) 2021-04-22
WO2021075535A1 (ja) 2021-04-22
KR20220103111A (ko) 2022-07-21
JP2025157483A (ja) 2025-10-15
EP4035679A4 (en) 2024-08-07
AU2020368759A1 (en) 2022-05-19
EP4035679A1 (en) 2022-08-03
US20230025003A1 (en) 2023-01-26

Similar Documents

Publication Publication Date Title
JP2023139101A (ja) 幹細胞遊走剤を使用した糖尿病治療
EP3615694B1 (en) Il-8, il-6, il-1b and tet2 and dnmt3a in atherosclerosis
Moreno-Loaiza et al. IL-1β enhances susceptibility to atrial fibrillation in mice by acting through resident macrophages and promoting caspase-1 expression
US20240139129A1 (en) Novel method and agent for treating, diagnosing and detecting diabetes and complications
TWI359271B (en) Pharmaceutical composition for insulin resistance
HK40073293A (en) Diabetes therapy targeting abnormal stem cells
CN114828891A (zh) 以异常干细胞为靶标的糖尿病治疗
Sonner et al. A GDF-15–GFRAL axis controls autoimmune T cell responses during neuroinflammation
HK40073547A (en) Therapy for diabetes using stem cell migration agent
HK40073790A (en) Diabetes therapy targeting abnormal stem cells
HK40074315A (en) Therapy for diabetes using stem cell migration agent
HK40105070A (en) Novel method and agent for treating, diagnosing and detecting diabetes and complications
JP6332780B2 (ja) 医薬組成物又は食品組成物、及び有効成分の体内での効果の評価方法
JP5830329B2 (ja) 腎障害の新規マーカー
EP4424327A1 (en) Method or agent with hdac regulator, for treatment of diabetes and complications
CA2801162A1 (en) Diagnostic, screening and therapeutic applications of ocab-based tools
Wu et al. Dapagliflozin targets RORγt to improve myocardial ischemia-reperfusion injury-induced heart failure by regulating the CD4+ T cell/Th17 cell axis within cardiac tissue
Shen et al. Aerobic exercise improves ventricular remodeling by promoting macrophages to phagocytose dying cardiomyocytes in heart failure model
Yi et al. Targeting the Mapk13‐Tcf1‐Slc7a5 Axis via One‐Carbon Metabolic Regulation to Prevent Chronic Allograft Vasculopathy
CN116036286A (zh) S100a7在肺鳞状细胞癌免疫检查点抑制剂治疗中的应用
Ahluwalia et al. Optimizing Vitamin D Levels in Patients with Multiple Sclerosis

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40073293

Country of ref document: HK